NCT00640497 - Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Acute Graft Versus Host Disease

Interventions

BIOLOGICAL

IT-Combination

The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.

Trial Locations (3)

6525 GA

Department of Hematology Radboud University Nijmegen (RUN), Nijmegen

3153075 EA

Department of Hematology Erasmus MC/Daniel den Hoed Cancer CenterGroene Hilledijk, Rotterdam

1003584 CX

L.F. , Department of HematologyUMC Utrecht, Utrecht